Harwood Feffer LLP Announces Investigation of AcelRx Pharmaceuticals, Inc.

NEW YORK, Oct. 7, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX), concerning whether the board has breached its fiduciary duties to shareholders.

One of AcelRx's products is called Zalviso.  Zalviso is a pain management system consisting of tablets delivered by a needle-free, handheld, patient-administered technique.  On July 25, 2014, after the market closed, AcelRx announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") regarding its New Drug Application for Zalviso. The FDA requested additional information on the Zalviso System to ensure proper use of the device, including changes to the Instructions for Use for the device and additional data to support the shelf life of the product.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own AcelRx shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: [phone]
[phone]
Email:  [e-mail]
Website:  http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm. 

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP

Copyright 2014 PR Newswire